We are live on
!
Find out more
Two Sigma Investments Portfolio holdings
AUM
$124B
1-Year Est. Return
33.93%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+33.93%
3 Year Est. Return
+96.56%
5 Year Est. Return
+105.93%
10 Year Est. Return
+538.88%
AUM
$42.6B
AUM Growth
-$927M
(-2.1%)
Cap. Flow
-$4.42B
Cap. Flow
% of AUM
-10.38%
Top 10 Holdings %
Top 10 Hldgs %
9.02%
Holding
3,518
New
408
Increased
1,022
Reduced
1,392
Closed
532
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOLD
2601
Boundless Bio
BOLD
$65M
| $242K | ﹤0.01% |
+17,000
| New | +$242K |
|
2602
UMB Financial
UMBF
$11.1B
| $242K | ﹤0.01% |
2,784
+84
| +3% | +$6.83K |
|
|
AOMR
2603
Angel Oak Mortgage REIT
AOMR
$209M
| $242K | ﹤0.01% |
22,542
+2,153
| +11% | +$22.8K |
|
2604
Star Group
SGU
$423M
| $242K | ﹤0.01% |
24,118
+4,758
| +25% | +$52.9K |
|
2605
CNA Financial
CNA
$14.1B
| $242K | ﹤0.01% |
5,319
-37,170
| -87% | -$1.64M |
|
|
KLRS
2606
Kalaris Therapeutics
KLRS
$96.8M
| $240K | ﹤0.01% |
13,819
+2,317
| +20% | +$37.8K |
|
2607
Hecla Mining
HL
$11.3B
| $239K | ﹤0.01% |
+49,661
| New | +$198K |
|
2608
RELX
RELX
$62B
| $238K | ﹤0.01% |
5,500
-19,300
| -78% | -$816K |
|
2609
ReNew
RNW
$2.25B
| $238K | ﹤0.01% |
39,600
-42,500
| -52% | -$280K |
|
2610
Epsilon Energy
EPSN
$173M
| $236K | ﹤0.01% |
42,930
-19,093
| -31% | -$95K |
|
|
RERE
2611
ATRenew
RERE
$1.01B
| $236K | ﹤0.01% |
133,872
+17,356
| +15% | +$23.1K |
|
|
VSXY
2612
PUT
Victoria's Secret
VSXY
$7.83B
| $234K | ﹤0.01% |
+12,100
| New | +$297K |
|
|
COOP
2613
PUT
DELISTED
Mr. Cooper
COOP
| $234K | ﹤0.01% |
+3,000
| New | +$209K |
|
2614
Lindsay Corp
LNN
$1.18B
| $233K | ﹤0.01% |
+1,983
| New | +$246K |
|
2615
Aquestive Therapeutics
AQST
$494M
| $233K | ﹤0.01% |
54,746
-112,413
| -67% | -$374K |
|
|
TPC
2616
PUT
Tutor Perini Cor
TPC
$5.21B
| $233K | ﹤0.01% |
16,100
-2,000
| -11% | -$20.4K |
|
2617
Tencent Music
TME
$15.6B
| $233K | ﹤0.01% |
20,800
-161,000
| -89% | -$1.58M |
|
|
ELP
2618
DELISTED
Companhia Paranaense de Energia (COPEL)
ELP
| $231K | ﹤0.01% |
29,880
-16,357
| -35% | -$133K |
|
2619
United States Lime & Minerals
USLM
$3.44B
| $229K | ﹤0.01% |
3,845
-13,740
| -78% | -$709K |
|
|
SIX
2620
DELISTED
Six Flags Entertainment Corp.
SIX
| $229K | ﹤0.01% |
8,700
-48,300
| -85% | -$1.21M |
|
|
INZY
2621
DELISTED
Inozyme Pharma
INZY
| $229K | ﹤0.01% |
29,893
-23,807
| -44% | -$131K |
|
|
HSHP
2622
Himalaya Shipping
HSHP
$748M
| $228K | ﹤0.01% |
29,624
-3,251
| -10% | -$24K |
|
2623
MINISO
MNSO
$3.75B
| $227K | ﹤0.01% |
11,095
-81,901
| -88% | -$1.57M |
|
2624
Seneca Foods Class A
SENEA
$1.21B
| $227K | ﹤0.01% |
3,993
-1,904
| -32% | -$99K |
|
2625
Novanta
NOVT
$6.29B
| $227K | ﹤0.01% |
+1,300
| New | +$213K |
|
Similar funds
VAM
Two Sigma Investments's Q1 2024 Portfolio in Review
As of Q1 2024, Two Sigma Investments held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Two Sigma Investments withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Two Sigma Investments opened a new position in Pfizer worth $234M.
- Two Sigma Investments's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- Two Sigma Investments added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- Two Sigma Investments's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- Two Sigma Investments fully exited Rivian in Q1 2024, selling an estimated $158M.
- Two Sigma Investments's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- Two Sigma Investments opened 408 new positions and closed 532 in Q1 2024.
- Two Sigma Investments's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.